Sullivan Ryan T 4
4 · INTERCEPT PHARMACEUTICALS, INC. · Filed Nov 15, 2019
Insider Transaction Report
Form 4
Sullivan Ryan T
General Counsel
Transactions
- Exercise/Conversion
Common Stock
2019-11-13$53.41/sh+500$26,705→ 26,929 total - Sale
Common Stock
2019-11-13$85.00/sh−500$42,500→ 26,429 total - Tax Payment
Common Stock
2019-11-13$83.92/sh−711$59,667→ 25,718 total - Exercise/Conversion
Option to Purchase Common Stock
2019-11-13−500→ 34,800 totalExercise: $53.41Exp: 2028-02-13→ Common Stock (500 underlying)
Footnotes (3)
- [F1]This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]Represents shares of common stock withheld by the Issuer to satisfy taxes associated with the partial vesting of a restricted stock award previously granted to the reporting person.
- [F3]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial installment on the anniversary of the Vesting Start Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Start Date was February 13, 2018.